From the Department of Mental Health and Pathological Addictions, Azienda USL di Parma, Parma, Italy.
J Clin Psychopharmacol. 2022;42(1):31-36. doi: 10.1097/JCP.0000000000001495.
PURPOSE/BACKGROUND: Although the prevalence of mental disorders in prisoners is known to be higher than in the general population, less is known about the antipsychotic (AP) prescribing rate in jail. The aim of this research was to investigate prevalence and appropriateness of AP prescription in an Italian prison to expand our understanding on this crucial area of clinical-forensic practice.
METHODS/PROCEDURES: A cross-sectional (census day) design was used among male adults in the Parma Penitentiary Institutes (PPI). Sociodemographic, clinical and prescription data were collected from the PPI electronic clinical database management system. The AP prescribing appropriateness was examined in accordance with the therapeutic indications included in the Italian National Formulary. A descriptive statistical analysis was performed.
FINDINGS/RESULTS: A total of 98 (14.1%) of 696 PPI prisoners were taking AP medications. Moreover, 90 (91.8%) of the 98 PPI participants were also taking other psychotropic medications concurrently. Quetiapine and olanzapine were the most common prescribed APs. Antipsychotic medications were most likely to be prescribed for off-label indications (74.4%). Less than one fifth of all AP prescriptions were for psychotic disorders.
IMPLICATIONS/CONCLUSIONS: Antipsychotic medications are widely used in prison, often together with other psychotropic drugs. Considering their common adverse effects, it is crucial to longitudinally monitor their potential risk of metabolic, cardiovascular, and extrapyramidal symptoms and signs, as well as their early risk of mortality. Given the high prevalence of AP off-label prescription, the rationale for AP prescribing should be clearly documented and regularly reviewed within the prison by mental health professionals.
目的/背景:尽管已知囚犯中心境障碍的患病率高于一般人群,但监狱中抗精神病药物(AP)的处方率知之甚少。本研究旨在调查意大利监狱中 AP 处方的流行率和适当性,以扩大我们对这一关键临床法医实践领域的理解。
方法/程序:采用横断面(普查日)设计,对帕尔马监狱学院的成年男性进行研究。从 PPI 电子临床数据库管理系统中收集社会人口统计学、临床和处方数据。根据意大利国家处方中包含的治疗指征,检查 AP 处方的适当性。进行描述性统计分析。
结果/发现:共有 696 名 PPI 囚犯中的 98 名(14.1%)正在服用 AP 药物。此外,98 名 PPI 参与者中的 90 名(91.8%)还同时服用其他精神药物。喹硫平和奥氮平是最常见的处方 AP。抗精神病药物最有可能被开用于标签外的适应症(74.4%)。不到五分之一的 AP 处方用于治疗精神病。
抗精神病药物在监狱中广泛使用,通常与其他精神药物一起使用。考虑到它们常见的不良反应,必须对代谢、心血管和锥体外系症状和体征以及早期死亡率的潜在风险进行纵向监测。鉴于 AP 标签外处方的高流行率,精神卫生专业人员应在监狱内明确记录和定期审查 AP 处方的理由。